Petmed Express INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
PetMed Express reported a significant 19.9% drop in net sales for the second quarter of fiscal year 2026, alongside continued operating losses and a substantial decrease in cash.
NASDAQ
PetMed Express reported a significant net loss and revenue decline for the quarter and nine months ended December 31, 2025, alongside a financial restatement, goodwill impairment, and ongoing review of unsolicited acquisition proposals.
NASDAQ
PetMed Express, Inc. reported a significant net loss and substantial revenue decline for the quarter and six months ended September 30, 2025, alongside a restatement of prior period financials and a $27.3 million impairment charge.
NASDAQ
PetMed Express reports a significant net loss of $34.15 million for Q1 2026, driven by a $27.26 million goodwill and intangible asset impairment and a 22.7% drop in net sales.
NASDAQ
PetMed Express reports a decrease in net sales for the quarter ended December 31, 2024, driven by a strategic reduction in advertising spend.
NASDAQ
PetMed Express experienced a decrease in sales for the second quarter of fiscal year 2025, alongside a strategic reduction in marketing spend and a change in the definition of a new customer.
NASDAQ
PetMed Express experienced a 13.2% decrease in sales for the quarter ended June 30, 2024, compared to the same period last year, alongside a net loss, and is addressing material weaknesses in internal controls.
NASDAQ
PetMed Express reports a net loss for the third quarter of fiscal year 2024, impacted by a restatement of prior financials and ongoing integration of PetCareRx, while also seeing a rise in sales and gross profit.
NASDAQ
PetMed Express has filed an amended quarterly report to restate its financials due to errors in sales tax accruals and valuation of deferred tax assets, impacting previously reported results.
NASDAQ
PetMed Express has filed an amended quarterly report to restate its financials for the three months ended June 30, 2023, and 2022, due to errors in sales tax accruals and valuation of deferred tax assets related to the PetCareRx acquisition.